pharmaceutical investing Catalyst Biosciences Announces Korean Ministry of Food and Drug Safety Approves Addition of Sixth Cohort to the Phase 1/2 Trial of CB 2679d/ISU304
pharmaceutical investing Portola Pharmaceuticals Announces New Interim Results from Ongoing ANNEXA-4 Study of Factor Xa Inhibitor Reversal Agent AndexXa
Ezutromid Significantly Reduced Muscle Damage in DMD Patients in 24-Week Interim Data From Summit’s PhaseOut DMD Clinical Trial
gold investing Roxgold Announces Interim Results of Bagassi South Infill and Extensional Drilling Program for the QV Prime Structure
market news Second Intersection Confirms Further Uranium on C10 Trend at CanAlaska's West McArthur Project
